DUBLIN--(BUSINESS WIRE)--The "High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecasts to 2023" report has been added to ResearchAndMarkets.com's offering.
The global HPAPI market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%.
The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.
While the HPAPI market presents significant growth opportunities, market growth may be hindered factors like requirement of large investments, discrepancies in HPAPI banding systems, uncertainties associated with products and high risk of cross-contamination are the major factors.
This report segments the HPAPIs market into type, type of manufacturer, type of synthesis, and therapeutic application.
Based on type, in 2018, the innovative HPAPIs segment is expected to account for the largest share of the market. The large share can be attributed to the increased investments of innovator companies in R&D, manufacture, marketing, and supply of innovative HPAPIs as the revenue generated from these molecules are considerably high.
On the basis of type of manufacturer, the captive HPAPI manufacturers segment is expected to account for the largest share of the market. The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for economic benefits.
On the basis of type of synthesis, the synthetic HPAPI segment is expected to command the largest share in 2018. The increasing emergence of new molecules in the market, rising number of product approvals, technological advancements in synthesis, and ease of production are driving the growth of the synthetic HPAPI segment.
On the basis of therapeutic application, the oncology segment is expected to account for the largest share of the global HPAPI market in 2018. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this segment.
- AstraZeneca plc
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly and Company
- F. Hoffmann-La Roche
- GlaxoSmithKline plc
- Merck & Co.
- Mylan Inc.
- Novartis International AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/ltf8hk/the_global_market?w=4